A weekly look at what the research actually says about the health topics everyone has an opinion on — supplements, sleep, nutrition, longevity, and the marketing sold alongside them. Where the evidence is strong, where the hype outruns the data, and how to tell the difference. Opinionated, never sponsored, 15–20 minutes, no filler. Educational content — not medical advice.
18 episodes
Walk into a forest after a bad day, and within minutes you may feel calmer. But can that calm be measured? In one small study, thirteen nurses spent two days among trees, and researchers found changes in their blood that lasted over a week. What was going on inside their bodies? And does it actually mean anything for your health?
13 min
Walk into a forest after a bad day, and within minutes you may feel calmer. But can that calm be measured? In one small study, thirteen nurses spent two days among trees, and researchers found changes in their blood that lasted over a week. What was going on inside their bodies? And does it actually mean anything for your health?
In a mouse, curcumin lowers COX-2, an inflammation enzyme. In a dish, it quiets the pathways that switch inflammation on. Yet in people, even after a huge dose, blood levels can be undetectable. So why does a compound that looks so powerful in the lab give such uneven results in human inflammation trials? And is absorption really the whole story?
A three-year-old girl, a zinc tablet dissolved in her mouth, and cold symptoms that vanished. That small story launched a surprisingly contested field. This episode asks why zinc seems to work only as a certain kind of lozenge, why most shelf products may not match what was tested, and where the researchers genuinely disagree, including what happens when the dose climbs too high.
Paracetamol is among the most used drugs on earth, and its own researchers still can't say precisely how it works. This episode tracks the competing theories, including a metabolite that reaches into the brain's pain and cannabinoid systems. Then we turn to the same drug's dangerous side: how an overdose can destroy the liver, and why the antidote has to come early.
A short walk after eating has trial evidence behind it — including crossover data in real patients — showing meaningful reductions in post-meal glucose. Berberine has a 37-trial meta-analysis behind it. And yet the popular idea of combining the two into a stacking protocol has never been directly tested. This episode works through what the evidence actually shows for each, and where the marketing has quietly outrun the science.
A gut bacterium called Lawsonibacter asaccharolyticus has emerged from the largest microbiome study ever conducted on coffee drinking — nearly 55,000 participants — with an association so consistent it resembles a fingerprint. Now a viral claim says this bacterium lowers your blood pressure and blood sugar. Some of that story rests on solid ground. Some of it doesn't. The distinction is worth understanding carefully.
Six billion dollars and a simple promise: your body makes less collagen as you age, so supplement it from outside. But a 2025 meta-analysis found something striking — when you remove industry funding from the skin trial literature, the benefit disappears entirely. Meanwhile, the joint evidence tells a different story. And buried inside the marketing is a product distinction that almost nobody makes clearly.
Cardiorespiratory fitness is one of the strongest predictors of longevity in all of preventive medicine — with effect sizes that dwarf smoking and diabetes in some analyses. But the evidence behind that claim is more complicated than it first appears. This episode examines what the data actually show, what a landmark randomised trial found when it put the question to a direct test, and what all of that means for the supplements marketing themselves against exercise as their benchmark.
The supplement industry has long marketed post-workout protein as time-sensitive — miss the window, lose the gains. But a 2013 meta-analysis pooling 23 randomised controlled trials found something uncomfortable: when researchers controlled for total daily intake, the timing effect largely disappeared. This episode examines what that finding actually means, where the daily intake ceiling sits, and how protein powder compares to whole food.
A fiber supplement with a meaningful clinical evidence base, good regulatory standing on three continents, and a tolerability profile that outperforms some of the most widely used alternatives — and most people in the gut health space have never heard of it. This episode works through what the research actually shows about partially hydrolyzed guar gum: what it does in the gut, who it appears to help, and where the evidence runs genuinely thin.
Ashwagandha has better clinical trial support than almost anything else in the adaptogen category — multiple meta-analyses, peer-reviewed journals, measurable effects on cortisol and anxiety. That evidence is real. But two questions rarely get the same airtime: whether emotional blunting is a documented adverse effect pattern, and whether the liver injury case reports in the medical literature represent a genuine safety signal worth taking seriously.
Two major clinical trials tested omega-3 fatty acids in comparable high-risk patient populations, at comparable doses, and reached opposite conclusions on cardiovascular outcomes. The gap between them turns on a disputed placebo choice, a competing hypothesis about which specific compound actually matters, and a risk signal running in the wrong direction. That is what this episode examines.
The vitamin D story most people have heard goes like this: widespread deficiency is driving cancer and heart disease, and generous supplementation will fix both. The largest randomised trial ever run on that question found it is mostly wrong — but the details of exactly where the evidence landed, and for whom it might still matter, are more interesting than either conclusion suggests.
The sleep supplement industry is worth billions, and the shelves are full of magnesium, glycine, L-theanine, and melatonin. The evidence for some of these compounds is real — but it applies to specific mechanisms and specific people. This episode works through what that evidence actually shows, and why melatonin in particular may be one of the most widely misunderstood supplements on the market.
More than half of American adults fall short of the daily magnesium requirement — and the supplement industry has responded with a dozen competing forms, each claiming superiority for sleep, cognition, or cardiovascular health. But before the form debate makes any sense, there's a prior problem: the deficiency numbers in the scientific literature range from 1.5 percent to 67.8 percent, and both figures are peer-reviewed. Understanding why takes you somewhere the marketing never goes.
The NAD+ supplement market is now worth billions of dollars, built on a chain of reasoning that runs from aging biology through animal studies to the pills people are actually buying. Some of that chain holds up. Some of it doesn't. And a regulatory dispute with the FDA reveals something important about how this entire product category reached consumers before the human clinical evidence was in place to support it.
Berberine has been used in traditional medicine for over a thousand years. In the last few years, it found a new identity: "nature's Ozempic." That single comparison drove enormous sales and a wave of TikTok content. This episode looks at what berberine actually does metabolically, how strong the clinical evidence really is — and why the GLP-1 comparison tells you almost nothing accurate about either compound.
Creatine monohydrate has been studied continuously for about 25 years — and unlike most supplements, the evidence has held up. This episode covers what the research actually shows about physical performance, emerging findings on the brain, and what's genuinely known versus still unresolved about women and older adults. The science is more settled in some areas than others, and the distinction matters.